Omnix Medical Granted Fast-Track Designation by U.S. FDA for its Next-Generation Anti-Infective OMN6
February 20, 2024 04:00 ET
|
AKAMPION
- Designation underlines the need for novel, first-in-class antimicrobials for the treatment of infections with Gram-negative bacteria JERUSALEM, Israel, February 20, 2023 -- Omnix Medical, a...
EBViously Presents Novel In-Vitro Data Demonstrating Potent Infection Prevention of its Vaccine Candidate EBV-001
December 04, 2023 04:00 ET
|
AKAMPION
Presentation at the World Vaccine Congress West Coast2023EBV-001 is designed for the prevention of Epstein-Barr Virus (EBV)-induced diseases via high titers of potent, neutralizing antibodiesNovel...
Study Published in Science Translational Medicine Shows Exbaq’s Experimental Vaccine Protects Against Many of the Most Dangerous Antibiotic Resistant Superbugs Causing Hospital Acquired Infections
October 05, 2023 09:00 ET
|
Exbaq LLC
Vaccine Stimulates the Body’s Macrophages, Engulfing and Killing Gram Positive/Negative Bacteria, and FungiVaccine provides protection against infections within 24hours and protection lasts for up to...
OpGen Reports Second Quarter 2023 Financial Results and Provides Business Update
August 10, 2023 16:15 ET
|
OpGen, Inc.
Total revenue for the first half of 2023 was approximately $1.65 million, an increase of approximately 15% compared to approximately $1.44 million in the first half of 2022Signed FIND R&D...
OpGen to Provide Business Update and Financial Results for the Second Quarter 2023 on August 10th at 4:30 p.m. Eastern Time
August 03, 2023 07:30 ET
|
OpGen, Inc.
ROCKVILLE, Md., Aug. 03, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its second quarter...
OpGen to Provide Business Update and Financial Results for the First Quarter 2023 on May 15th at 4:30 p.m. Eastern Time
May 08, 2023 07:30 ET
|
OpGen, Inc.
ROCKVILLE, Md., May 08, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its first quarter...
OpGen’s Subsidiary Curetis Signs Expansion of R&D Collaboration with FIND
April 05, 2023 07:30 ET
|
OpGen, Inc.
Parties add several deliverables to initial R&D collaboration contractOverall potential revenue increased to up to euro 830 thousand ROCKVILLE, Md., April 05, 2023 (GLOBE NEWSWIRE) -- OpGen,...
New to The Street TV Announces its Business Guest Interviews, Episode #388 Airs on Bloomberg TV, Saturday, September 24, 2022, at 6:00 PM ET as Sponsored Programming
September 23, 2022 10:15 ET
|
FMW Media Works Corp
NEW YORK, Sept. 23, 2022 (GLOBE NEWSWIRE) -- FMW Media’s New to The Street TV announces broadcasting its sponsored program business show Saturday, September 24, 2022, on Bloomberg TV at 6:00 PM ET....
Fungal Keratitis Treatment Market Size is projected to reach USD 1.32 Billion by 2030, growing at a CAGR of 6%: Straits Research
July 14, 2022 13:00 ET
|
Straits Research
New York, United States, July 14, 2022 (GLOBE NEWSWIRE) -- The fungal keratitis treatment market is driven by the increasing prevalence of such diseases worldwide, rising awareness of the potential...
MicroGenDX First Independent Commercial Lab in US Offering NGS for Infections to Appeal Directly to Patients
January 24, 2022 18:07 ET
|
Microgen Diagnostics
ORLANDO, Fla., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Using national TV, radio, and web media campaigns, Microgen Diagnostics will be the first independent commercial lab in the U.S. to appeal directly...